CO01 | Statin therapy for the prevention of venous thromboembolism in cancer patients: a systematic review and meta-analysis
F. Catalani, R. Del Giorno, R. Canevascini, W. Ageno, L. Gabutti, G. Prouse, L. Giovannacci | Ospedale Regionale di Bellinzona, Switzerland.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Background and Aims: Venous thromboembolism (VTE) in cancer patients might produce severe clinical consequences such as anticancer therapies delay, hospitalization, and increased risk of both thrombotic recurrence and bleeding during anticoagulant therapy; moreover, in these patients, VTE is the second leading cause of death after cancer itself, reducing overall survival rates. If previous studies already suggested a potential role of statins in preventing VTE in the general population, there is still paucity of evidence concerning statins’ effect in the prevention of cancer-associated thrombosis. This systematic review and meta-analysis aims at filling this gap, by evaluating statins’ role in VTE prevention in cancer patients.
Methods: We systematically searched PubMed, Embase and Cochrane Library from inception to May 2024, for randomized controlled trials (RCTs) and observational studies including patients treated with statins (compared to either placebo or non-statin treatment), reporting on the incidence of VTE during follow-up. Information on study characteristics and incidence of VTE were extracted. Estimates were pooled using random-effects meta-analysis.
Results: We identified 111 potential studies, 12 were included in the analysis, 2 RCTs and 10 observational studies, for a total of 186.726 patients. Statins were associated with a 30% reduction of the risk of VTE (RR: 0.70; 95%CI: 0.50–0.87), compared to no statin treatment (Fig. 1). A significant heterogeneity was found among the included studies (I2 = 70).
Conclusions: According to our preliminary results, treatment with statins in cancer patients seems to reduce the incidence of VTE events. High quality prospective studies are strongly needed in order to better establish statins’ role in this subset of patients.
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Similar Articles
- Alice Lipari, Esmeralda Capristo, Antonietta Ferretti, Erica De Candia, Anticoagulation in obese patients: challenges and strategies , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 3 (2025)
- Stefania Cavazza, Gualtiero Palareti*, Still unmet problems with low molecular weight heparin prophylaxis of venous thromboembolism. An Italian survey , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 3 (2025)
- CS04 | Association between elevated plasma levels of tissue plasminogen activator and occult cancer risk: a nested case-cohort analysis in 10,294 healthy subjects , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Ronda Lun, Deborah M. Siegal, Cancer-associated ischemic stroke: current knowledge and future directions , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
- Gary E. Raskob, Risk of recurrent venous thromboembolism in cancer patients after discontinuation of anticoagulant therapy , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
- Agnes Y.Y. Lee, Venous thromboembolism treatment in patients with cancer: reflections on an evolving landscape , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
- CO06 | Recurrences of catheter associated upper extremity deep vein thrombosis in cancer: a two year prospective study with enoxaparin , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Mehrie H. Patel, Alok A. Khorana, New drugs, old problems: immune checkpoint inhibitors and cancer-associated thrombosis , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
- Marcello Di Nisio, Matteo Candeloro, Nicola Potere, Ettore Porreca, Jeffrey I. Weitz, Factor XI inhibitors: a new option for the prevention and treatment of cancer-associated thrombosis , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
- PO81 | Direct oral anticoagulants in atypical site vein thrombosis: a single centre experience focused on cancer patients , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
You may also start an advanced similarity search for this article.
